Breaking news

WHO’s Historic Agreement: A Major Step Towards Global Pandemic Preparedness

In a groundbreaking move, members of the World Health Organization (WHO) have reached a historic, legally binding agreement aimed at preparing the world for future pandemics. This pact, designed to address the lessons learned from the COVID-19 crisis, sets the stage for a more equitable global response to health emergencies, particularly in the distribution of essential drugs, vaccines, and medical technologies.

The agreement marks a significant milestone in global health governance, especially at a time when multilateral institutions like the WHO are facing considerable financial strain. The United States, which was once the WHO’s largest financial contributor, withdrew from negotiations after President Donald Trump initiated the U.S.’s departure from the organization. Despite this setback, the deal underscores a strong commitment from member states to work together on global health security, with or without U.S. involvement. “This is a historic moment,” said Nina Schwalbe, founder of global health think tank Spark Street Advisors. “It demonstrates that countries are committed to multilateralism and to collective action.”

This agreement, the second of its kind in WHO’s 75-year history (the first being a tobacco control treaty in 2003), focuses on structural inequalities in how pandemic-related health tools are developed and distributed. Article nine of the deal ensures that future pandemic-related drugs, therapeutics, and vaccines will be made globally accessible. It also gives the WHO stronger oversight over medical supply chains and paves the way for local production of vaccines during health crises.

A key challenge in the negotiations was the issue of technology transfer—sharing the knowledge and manufacturing capabilities necessary for lower-income countries to produce their vaccines and treatments. To address this, the agreement mandates that manufacturers allocate at least 20% of their real-time production to the WHO during a pandemic, with a minimum of 10% designated for donation and the rest priced affordably for developing nations.

The deal is not yet finalized, as it must be adopted at the WHO Assembly in May, and some details, such as the annex on Pathogen Access and Benefit Sharing, still require further negotiation. However, once ratified, the agreement will bolster global preparedness, enabling quicker responses to future pandemics and more equitable access to life-saving resources.

As health experts emphasize, the global community must invest in preparedness now to avoid the costly toll of another pandemic. “We can’t afford another pandemic, but we can afford to prevent one,” said Helen Clark, co-chair of The Independent Panel for Pandemic Preparedness. This agreement represents a critical step toward ensuring that the world is better equipped to face future health crises with solidarity, transparency, and a commitment to equity.

Bank of Cyprus Upgrade Signals Fresh Optimism For Greek And Cypriot Banks

Regional Banks Enter A More Favorable Cycle

Bank of Cyprus and Eurobank are well positioned to benefit from a renewed re-rating of Greek and Cypriot bank stocks, according to Cyprus-based investment firm Roemer Capital, which upgraded Bank of Cyprus to a buy rating and reaffirmed its positive view on Eurobank.

The firm cited easing geopolitical tensions, resilient economic growth in Greece and Cyprus, lower funding costs and Greece’s expected transition to developed-market status as the main factors supporting the sector.

Roemer Capital also lowered its cost of equity assumptions, updated its forecasts following first-quarter 2026 results and extended its valuation horizon to the end of 2027, raising target prices across its banking coverage.

Bank Of Cyprus Gets The Largest Upgrade

Bank of Cyprus received the biggest revision, with Roemer Capital upgrading the stock from hold to buy and setting a target price of €11.10, implying potential total upside of 27%.

The firm highlighted the bank’s strong capital generation, profitability and projected 100% dividend payout, describing it as the strongest capital-return story among the banks under coverage. Roemer Capital maintained its buy rating on Eurobank, assigning a target price of €4.90 and forecasting potential upside of 28%. The report said the bank is well placed to benefit from loan growth, improving operating performance and merger-and-acquisition synergies.

National Bank of Greece and Piraeus Bank also retained buy ratings, with expected returns ranging from 25% to 36%. Optima Bank was upgraded to buy, while Alpha Bank remained at hold on valuation grounds.

Why Growth Still Sets The Region Apart

According to Roemer Capital, Greek and Cypriot banks continue to benefit from stronger economic fundamentals than many western European peers. The report pointed to faster economic growth, healthier balance sheets, low levels of non-performing exposures, capital ratios approaching 20% and strong customer deposit bases.

Analysts expect performing loans across the sector to grow at a compound annual rate of 6% to 8% through 2028, supported by private investment, digitalisation, green manufacturing, supply-chain expansion and a gradual recovery in household lending.

The report also said the conclusion of lending under the EU Recovery and Resilience Facility is unlikely to materially affect credit growth, as banks have already shifted back towards traditional commercial lending. Roemer Capital expects Euribor to remain between 2.2% and 2.5%, a level it believes should support both lending activity and net interest margins.

Geopolitics, Valuation And Market Structure Support The Case

The report said improving geopolitical conditions have strengthened the investment outlook, noting that Brent crude prices have largely returned to pre-war levels while Greek government bond yields have stabilised at around 3.5%. Although geopolitical risks remain, Roemer Capital believes the likelihood of a major inflationary shock or significant pressure on bank profitability has eased.

Another important catalyst identified by the firm is Greece’s expected promotion to developed-market status by FTSE Russell, STOXX and MSCI over the coming months.

According to the report, the reclassification should improve liquidity and attract a broader base of international investors. Roemer Capital also said Euronext’s acquisition of the Athens Exchange is expected to strengthen market infrastructure and increase international visibility, particularly for Bank of Cyprus and Optima Bank.

The firm noted that Bank of Cyprus has already benefited from its Athens listing, with average daily trading value increasing from less than €400,000 before its September 2024 move to nearly €6 million afterwards.

Economic Momentum Remains A Core Tailwind

Roemer Capital said both Greece and Cyprus have moved beyond post-crisis recovery and are now supported by private-sector-led growth. For Cyprus, the report highlighted recent tax reform and efforts to simplify the legal and regulatory framework, while also noting that limited foreign banking competition continues to support domestic lenders.

Overall, Roemer Capital expects Greek and Cypriot banks to remain well-positioned for profitable loan growth over the coming years.

Uol
The Future Forbes Realty Global Properties
Aretilaw firm
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter